Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Objectives: To investigate whether the conclusion of a recent systematic review and network meta-analysis (Cipriani et al) that antidepressants are more efficacious than placebo for adult depression was supported by the evidence. Design: Reanalysis of a systematic review, with meta-analyses. Data sources: 522 trials (116 477 participants) as reported in the systematic review by Cipriani et al and clinical study reports for 19 of these trials. Analysis: We used the Cochrane Handbook’s risk of bias tool and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to evaluate the risk of bias and the certainty of evidence, respectively. The impact of several study characteristics and publication status was estimated using pairwise subgroup meta-analyses. Results: Several methodological limitations in the evidence base of antidepressants were either unrecognised or underestimated in the systematic review by Cipriani et al. The effect size for antidepressants versus placebo on investigator-rated depression symptom scales was higher in trials with a ‘placebo run-in’ study design compared with trials without a placebo run-in design (p=0.05). The effect size of antidepressants was higher in published trials compared with unpublished trials (p<0.0001). The outcome data reported by Cipriani et al differed from the clinical study reports in 12 (63%) of 19 trials. The certainty of the evidence for the placebo-controlled comparisons should be very low according to GRADE due to a high risk of bias, indirectness of the evidence and publication bias. The mean difference between antidepressants and placebo on the 17-item Hamilton depression rating scale (range 0–52 points) was 1.97 points (95% CI 1.74 to 2.21). Conclusions: The evidence does not support definitive conclusions regarding the benefits of antidepressants for depression in adults. It is unclear whether antidepressants are more efficacious than placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies without active placebo are considered to be at unclear or high risk of performance bias (Munkholm 2019).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Munkholm 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of antidepressant treatment for depression is modest compared with placebo [2, 3]”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541 · cited 10×
“They classified the trials as low risk of bias if none of the domains assessed were rated as high risk of bias and three or less were rated as unclear risk; moderate if one domain was rated as high risk of bias or none were rated as high risk of bias but four or more were rated as unclear risk; and all other cases wer…”
InfluentialThe cost of dichotomising continuous variables
Altman, D. G., & Royston, P. (2006) · BMJ · doi:10.1136/bmj.332.7549.1080 · Cited by 2,688
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 2×
“antidepressant trials remain unpublished or are inadequately reported.(9) Cipriani et al(5) included 436 published and 86 unpublished studies, but as many as a thousand antidepressant studies may have been conducted.”
BackgroundIntHout, J., Ioannidis, J. P., & Borm, G. F. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-25 · Cited by 2,419 · cited 1×
“For the comparisons between antidepressants and placebo on rating scales, we used the Hartung-Knapp-SidikJonkman approach because it results in fewer type I errors than the DerSimonian and Laird approach.(16) We based our analyses on the number of participants from Cipriani et al’s ‘efficacy’ analyses.”
MethodAntidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845
GRADE guidelines: 8. Rating the quality of evidence—indirectness
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Falck-Ytter, Y., Jaeschke, R., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.04.014 · Cited by 1,843 · cited 1×
“Downgrading due to the indirectness of the network meta-analysis’ methodology should also be considered.(38) Taken together, the certainty of evidence should be ‘very low’.”
BackgroundIndustry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697 · cited 1×
“Some argue that ‘vested interests’ should also be considered, since industry sponsored drug studies lead to more favourable effects than other studies by mechanisms that are not explained by the usual bias domains.(26) We explored whether industry sponsorship was associated with larger effect estimates, by performing…”
Research works printed but not linked: 1
- Sharma T Effects of selective serotonin reuptake inhibitors (SSRIs) and serotonin - norepinephrine reuptake inhibitors (SNRIs) on suicidality, violence, and quality of life (PhD Thesis): University of Copenhagen, 2018.
Cited by
Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101809 · Cited by 354
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137
O’Connor, E., Perdue, L. A., Coppola, E. L., Henninger, M. L., Thomas, R. G., & Gaynes, B. N. (2023) · JAMA · doi:10.1001/jama.2023.7787 · Cited by 126
Hengartner, M. P., & Plöderl, M. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111600 · Cited by 114
Forest therapy can prevent and treat depression: Evidence from meta-analyses
Rosa, C. D., Larson, L. R., Collado, S., & Profice, C. C. (2020) · Urban forestry & urban greening · doi:10.1016/j.ufug.2020.126943 · Cited by 133
Gosmann, N. P., Costa, M. D. A., Jaeger, M. D. B., Motta, L. S., Frozi, J., Spanemberg, L., Manfro, G. G., Cuijpers, P., Pine, D. S., & Salum, G. A. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003664 · Cited by 85
“Controversy concerning antidepressants in the treatment of mood disorders [5,6] obscures vital questions for the treatment of other conditions, such as anxiety, obsessive-compulsive, and stress-related disorders.”
BackgroundAntidepressants in inflammatory bowel disease
Mikocka-Walus, A., Ford, A. C., & Drossman, D. A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0259-y · Cited by 93
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Eggart, M., Todd, J., & Valdés‐Stauber, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253913 · Cited by 84
Canadian Guideline for the Clinical Management of High-Risk Drinking and Alcohol Use Disorder
Wood, E., Bright, J., Hsu, K., Goel, N., Ross, J. W. G., Hanson, A., Teed, R., Poulin, G., Denning, B., Corace, K., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230715 · Cited by 74
“62 Additionally, given that medications alone are unlikely to be effective in many instances of AUD, the role of commonly prescribed medications (e.g., naltrexone, SSRI) in potentially augmenting or undermining psychosocial treat-ment interventions similarly deserves further study.”
BackgroundHengartner, M. P., Jakobsen, J. C., Sørensen, A., & Plöderl, M. (2020) · PLOS ONE · doi:10.1371/journal.pone.0229381 · Cited by 66
“[11], most studies were rated at high or unclear risk of bias with respect to allocation concealment and blinding of participants.”
BackgroundMethodResultInfluentialHengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01285-w · Cited by 65
Self-citationDepression in multiple sclerosis: Is one approach for its management enough?
Jones, C. D., Motl, R. W., & Sandroff, B. M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.102904 · Cited by 66
Placebos and the Placebo Effect in Drug Trials
Enck, P., & Klosterhalfen, S. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_269 · Cited by 68
Stone, J., Barker, T. H., Aromataris, E., Ritskes-Hoitinga, M. J., Sears, K., Klugar, M., Leonardi‐Bee, J., & Munn, Z. (2023) · JBI Evidence Synthesis · doi:10.11124/jbies-22-00434 · Cited by 59
Breeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58
Ahmadpanah, M., Ramezanshams, F., Ghaleiha, A., Akhondzadeh, S., Bahmani, D. S., & Brand, S. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112613 · Cited by 63
Mak, H. W., Coulter, R., & Fancourt, D. E. (2020) · PubMed · Cited by 71
Wand, T., Glover, S., & Paul, D. (2021) · International Journal of Mental Health Nursing · doi:10.1111/inm.12947 · Cited by 55
Liu, X., Chen, W., Wang, C., Liu, W., Hayashi, T., Mizuno, K., Hattori, S., Fujisaki, H., & Ikejima, T. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113593 · Cited by 49
Plöderl, M., & Hengartner, M. P. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-034816 · Cited by 51
Ang, B., Horowitz, M. A., & Moncrieff, J. (2022) · SSM - Mental Health · doi:10.1016/j.ssmmh.2022.100098 · Cited by 57
Volkmann, C., Volkmann, A., & Müller, C. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241497 · Cited by 43
“However, the so-called average treatment effect, which measures the difference in mean outcomes between active and control group, was only about 2 points on the 17-item Hamilton Depression Rating Scale (HAMD-17) [5] in this dataset [6].”
BackgroundSanwald, S., Widenhorn‐Müller, K., Schönfeldt‐Lecuona, C., Connemann, B. J., Gahr, M., Kammer, T., Montag, C., & Kiefer, M. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03166-6 · Cited by 41
Darcy, A., Beaudette, A., Chiauzzi, E., Daniels, J., Goodwin, K., Mariano, T. Y., Wicks, P., & Robinson, A. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2075726 · Cited by 40
“Pharmacological treatment Oral antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs); intravenous brexanolone for postpartum depression (PPD) [25]; intravenous ketamine for treatmentresistant depression (TRD); intranasal esketamine for TRD…”
BackgroundRetractedCheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz062 · Cited by 38
“Copyedited by: Cheng et al. | 83 A recently published meta-analysis (Munkholm et al., 2019) pointed out that the efficacy of antidepressants vs placebos was higher in trials with a placebo run-in study design compared with trials without such a design (P = .05); a lower efficacy was found in…”
ResultNeurodualism: People Assume that the Brain Affects the Mind more than the Mind Affects the Brain
Valtonen, J., Ahn, W., & Cimpian, A. (2021) · Cognitive Science · doi:10.1111/cogs.13034 · Cited by 38
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Meling, D., Ehrenkranz, R. C., Nayak, S. M., Aicher, H., Funk, X., van Elk, M., Graziosi, M., Bauer, P. R., Scheidegger, M., & Yaden, D. B. (2024) · Psychoactives · doi:10.3390/psychoactives3020014 · Cited by 35
“While not only including SSRIs but antide-pressants in general, a more recent meta-analysis found an overall SMD for antidepressants versus placebo of 0.29, 95% CI [0.27, 0.31], over 390 comparisons, k = 253 studies [67].”
BackgroundResultInfluentialAnatomy of a Woebot® (WB001): agent guided CBT for women with postpartum depression
Darcy, A., Beaudette, A., Chiauzzi, E., Daniels, J., Goodwin, K., Mariano, T. Y., Wicks, P., & Robinson, A. (2023) · Expert Review of Medical Devices · doi:10.1080/17434440.2023.2280686 · Cited by 28
“Pharmacological treatment Oral antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs); intravenous brexanolone for postpartum depression (PPD) [25]; intravenous ketamine for treatmentresistant depression (TRD); intranasal esketamine for TRD…”
BackgroundAicher, H. D., Mueller, M. J., Dornbierer, D. A., Suay, D., Elsner, C., Wicki, I., Meling, D., Caflisch, L., Hempe, A., Steinhart, C., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1302559 · Cited by 33
Arnold, M. M., Müller-Oerlinghausen, B., Hemrich, N., & Bönsch, D. (2020) · Brain Sciences · doi:10.3390/brainsci10100676 · Cited by 33
Horowitz, M., & Wilcock, M. (2022) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2020.000080 · Cited by 33
Dornbierer, D. A., Marten, L., Mueller, J., Aicher, H. D., Mueller, M. J., Boxler, M., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1246892 · Cited by 32
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis
Hieronymus, F., López, E., Sjögren, H. W., & Lundberg, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.24119 · Cited by 34
Read, J., Moncrieff, J., & Horowitz, M. A. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.013 · Cited by 30
Graff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., et al. (2023) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwad012 · Cited by 30
von Glischinski, M., von Brachel, R., Thiele, C., & Hirschfeld, G. H. F. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.041 · Cited by 33
The serotonin hypothesis of depression: both long discarded and still supported?
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., Plöderl, M., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02094-z · Cited by 33
“Antidepressants show marginal differences from placebo, which do not ful fi l criteria for clinical relevance, and may represent ampli fi ed placebo effects due to unblinding [31 – 33].”
A meta-analysis of cranial electrotherapy stimulation in the treatment of depression
Price, L. R., Briley, J., Haltiwanger, S., & Hitching, R. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.043 · Cited by 31
“…Assessment, Development and Evaluation (GRADE) approach to assess the risk of bias and caliber of clinical evidence did not find any definitive support for the recommendation that antidepressants as more efficacious than placebo in the management of major depression (Munkholm et al., 2019).”
BackgroundResultBoesen, K., Gøtzsche, P. C., & Ioannidis, J. P. A. (2021) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796021000147 · Cited by 26
“In specialities like oncology, this seems to be particularly prevalent (Kim and Prasad, 2015; Davis et al., 2017; Gyawali et al., 2019; Naci et al., 2019).”
BackgroundSelf-citationThe need for antidepressant withdrawal support services: Recommendations from 708 patients
Read, J., Lewis, S., Horowitz, M., & Moncrieff, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115303 · Cited by 24
“This emphasises the gap between what people were led to believe about these drugs and the actual experience of taking them, noting that the vast majority of studies on these drugs are short term (several weeks) and mostly conducted by their manufacturers (Munkholm, 2019),”
BackgroundConsistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements
Khan, A., Mar, K. F., & Brown, W. A. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4412 · Cited by 26
Individual response to antidepressants for depression in adults-a meta-analysis and simulation study
Munkholm, K., Homan, S., & Homan, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237950 · Cited by 24
“In addition, considering the methodological limitations of many antidepressant trials [19], the true effect of antidepressants for depression in adults remains uncertain [17].”
BackgroundMethodInfluentialSelf-citationMacrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Kaypak, A. C., & Raz, A. (2022) · Transcultural Psychiatry · doi:10.1177/13634615221119386 · Cited by 24
“For example, in the case of antidepressants, placebos and antidepressants seem clinically comparable for the treatment of mild-to-moderate depression (Kirsch, 2014; Munkholm et al., 2019).”
BackgroundCohen, S. E., Zantvoord, J. B., Storosum, B. W. C., Mattila, T., Daams, J. G., Wezenberg, B. N., de Boer, A., & Denys, D. A. J. P. (2024) · BMJ Mental Health · doi:10.1136/bmjment-2023-300951 · Cited by 23
“7 8 However, these results are derived from average treatment effects and did not take modifiers of effect into account.”
Deceptive and non-deceptive placebos to reduce sadness: A five-armed experimental study
Friehs, T., Rief, W., Glombiewski, J. A., Haas, J. W., & Κube, T. (2022) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2022.100349 · Cited by 22
Holper, L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.11.012 · Cited by 22
“It should also be considered that other covariates, such as depression severity or gender, as well as plausible risk of bias not accounted for by the covariates may also affect treatment recommendations, with the latter being primarily due to study limitations, imprecision, and publication bias, as revealed by an earl…”
Niedermoser, D. W., Kalak, N., Kiyhankhadiv, A., Brand, S., Walter, C., Schweinfurth, N., & Lang, U. E. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00168 · Cited by 21
“The results are important for clinicians because the newest meta-analysis (8) showed that it is unclear whether the antidepressive treatment is more efficacious than the placebo treatment.”
BackgroundKamp, C. B., Juul, S., Siddiqui, F., Barbateskovic, M., Munkholm, K., Hengartner, M. P., Kirsch, I., Gluud, C. N., & Jakobsen, J. C. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01789-0 · Cited by 21
“Finally, we expect short treatment and follow-up periods which may not accurately mimic how antidepressants are used in clinical practice [65, 66].”
BackgroundSelf-citationDesigning clinically useful psychopharmacological trials: challenges and ways forward
Chevance, A., Ravaud, P., Cornelius, V. R., Mayo‐Wilson, E., & Furukawa, T. A. (2022) · The Lancet Psychiatry · doi:10.1016/s2215-0366(22)00041-4 · Cited by 24
Neurobiological reduction: From cellular explanations of behavior to interventions
Parker, D. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.987101 · Cited by 18
“Novel Psychopharmacology for Depressive Disorders”
Fornaro, M., Berardis, D. D., Anastasia, A., & Fusco, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_22 · Cited by 16
Castillo, A., Dubois, J., Field, R. M., Fishburn, F. A., Gundran, A., Ho, W. C., Jawhar, S., Kates‐Harbeck, J., Aghajan, Z. M., Miller, N., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38258-8 · Cited by 16
Difficult lives explain depression better than broken brains
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02462-3 · Cited by 17
“This study found a difference of 5 points on the MADRS between the two groups, twice the antidepressant-placebo difference found in meta-analysis of antidepressants [42].”
Boussageon, R., Blanchard, C., Charuel, É., Ménini, T., Pereira, B., Naudet, F., Kassaï, B., Gueyffier, F., Cucherat, M., & Vaillant-Roussel, H. (2022) · Therapies · doi:10.1016/j.therap.2022.10.008 · Cited by 22
Bright light therapy for mental and behavioral illness: A systematic umbrella review
Reis, D. J., Hoffberg, A. S., Stearns‐Yoder, K. A., & Bahraini, N. H. (2022) · Chronobiology International · doi:10.1080/07420528.2022.2140669 · Cited by 16
“The observed effect sizes for depression were comparable in magnitude to those seen with both antidepressants and psychotherapy, indicating that BLT is a viable first-line treatment for depressive illness (Cuijpers et al. 2019; Munkholm et al. 2019).”
BackgroundResultAristodemou, M., Kievit, R., Murray, A. L., Eisner, M., Ribeaud, D., & Fried, E. I. (2023) · Clinical Psychological Science · doi:10.1177/21677026231162814 · Cited by 16
“However, “no established mechanism can explain all aspects of the disease” (Otte et al., 2016, p. 1), and the effectiveness of treatments targeting hypothesized common causes of depression is currently unclear or unsatisfactory (Bobo et al., 2016; Lv et al., 2019; Munkholm et al., 2019).”
BackgroundIs suicide a mental health, public health or societal problem?
Goel, D., Dennis, B. R., & McKenzie, S. (2023) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000888 · Cited by 15
Holper, L., & Hengartner, M. P. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02839-y · Cited by 16
Interventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 15
“This meta-analysis is deeply flawed [81,82].”
Maß, R., Backhaus, K., Lohrer, K., Szelies, M., & Unkelbach, B. K. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06417-4 · Cited by 13
A national study of the mental health literacy of community pharmacists
Rimal, R., Lin, J. C., Chan, A. H. Y., Chen, T. F., Sheridan, J. L., & Sundram, F. (2022) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2022.01.002 · Cited by 13
Has the time come to stop using control groups in trials of psychosocial interventions?
Cuijpers, P. J. (2025) · World Psychiatry · doi:10.1002/wps.21359 · Cited by 11
Plöderl, M., & Hengartner, M. P. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2230-4 · Cited by 12
Shahmoradi, N., Davarinejad, O., Brühl, A. B., & Brand, S. (2023) · Medicina · doi:10.3390/medicina59091663 · Cited by 10
Seekircher, J., Burgard, T., & Bošnjak, M. (2023) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000510 · Cited by 10
Jureidini, J. N., Moncrieff, J., Klau, J., Aboustate, N., & Raven, M. K. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231218623 · Cited by 10
“Antidepressant studies have been criticised for the underreporting of harms (Le Noury et al., 2016) and other methodological problems (Munkholm et al., 2019).”
Sezer, D., Locher, C., & Gaab, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-25446-1 · Cited by 8
TRPC4/5 inhibitors: Phase I results and proof of concept studies
Grimm, S., Just, S., Fuertig, R., Dwyer, J. B., Sharma, V., & Wunder, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01890-0 · Cited by 10
Kalbermatten, N., & Saller, R. (2025) · Complementary Medicine Research · doi:10.1159/000547920 · Cited by 8
“In trials for antidepressants, pronounced placebo-effects are a well-known, widely discussed phenomenon [3, 47].”
Arts and public mental health: exemplars from Scandinavia
Jensen, A., Torrissen, W., & Stickley, T. (2020) · VBN Forskningsportal (Aalborg Universitet) · Cited by 8
Wong, J., Kurteva, S., Motulsky, A., & Tamblyn, R. (2021) · Medical Care · doi:10.1097/mlr.0000000000001658 · Cited by 8
Poststroke Cardiovascular Management: Current Concepts, Integrated Care, and Future Developments
Lip, G. Y. H., Lenarczyk, R., Pastori, D., Ntaios, G., Doehner, W., & Schnabel, R. B. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101738 · Cited by 8
Using illicit drugs alone in Vancouver, Canada: a gender-based analysis
Gallant, K., Hayashi, K., Sayre, E. C., Choi, J., Mansoor, M., & Kerr, T. H. (2025) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-025-00637-x · Cited by 6
“Aside from emerging questions regarding the benefits of modern antidepressant medications [41, 55], a growing body of evidence suggests that these medications, in particular serotonergic antidepressants, are ineffective in substance using populations, and in some cases may exacerbate cravings and…”
Ansari, M., Balali-Dehkordi, S., Rahimi‐Madiseh, M., Zarean, E., & Amini-Khoei, H. (2025) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2025.2577759 · Cited by 6
“Despite widespread use of antidepressant drugs, these medications have notable limitations (Munkholm et al. 2019).”
Boesen, K., Jørgensen, K. J., & Gøtzsche, P. C. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.10.027 · Cited by 6
Self-citationHomeopathy for Major Depressive Disorder: Protocol for N-of-1 Studies
Adler, U. C., Adler, M. S., César, A. D. T., Santos, H. D. F., Magalhães, P. A. D. F., Nogueira, R. D. S., Campos, E. D. M., Júnior, A. B. V., & Sanders, L. L. O. (2023) · Complementary Medicine Research · doi:10.1159/000531072 · Cited by 6
Npbwr1 signaling mediates fast antidepressant action
Stein, G., Aly, J. S., Lange, L. D., Manzolillo, A., Riege, K., Brancato, A., Huebner, A. K., Turecki, G., Hoffmann, S., & Engmann, O. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02790-4 · Cited by 7
“Because current antidepressants work slowly, are only partially effective, and have common side effects [6 – 8], there is an unmet need to identify other, fast-acting pathways, to rapidly ameliorate symptoms of stress and depression in ways independent of known signaling such as serotonergic and…”
Wand, T. (2025) · Issues in Mental Health Nursing · doi:10.1080/01612840.2025.2476156 · Cited by 6
“Of additional concern is the lack of evidence for the effectiveness of antidepressants (Jakobsen et al., 2020; Munkholm et al., 2019) and their enduring adverse effect and withdrawal symptoms.”
da Cruz, L. V. M., Bienemann, B., Palhano-Fontes, F., Tófoli, L. F., de Araújo, D. B., & Mograbi, D. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-44193-5 · Cited by 13
Discontinuation of long-term antidepressant use for depressive and anxiety disorders in adults
Leeuwen, E. V., van Driel, M., Sutter, A. I. D., Anderson, K., Robertson, L., & Christiaens, T. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495 · Cited by 6
“However, there is also increasing criticism about the lack of evidence for eFectiveness of antidepressants in the acute treatment of mild to moderate depressive disorders, due to important limitations of the available evidence base (McCormak 2018; Munkholm 2019).”
BackgroundMaß, R., Backhaus, K., Szelies, M., & Unkelbach, B. K. (2023) · Verhaltenstherapie · doi:10.1159/000528902 · Cited by 5
“…es noch weitere methodische Probleme, z.B. die bereits erwähnte Publikationstendenz, minimale Unterschiede zwischen Verum- und Placebo-Gruppen an der Grenze zur klinischen Relevanz, Fehlinterpretation von Absetzeffekten als Rückfälle [Kirsch, 2016, 2019; Hengartner, 2017; Munkholm et al., 2019].”
BackgroundKamp, C. B., Juul, S., Siddiqui, F., Horowitz, M. A., Moncrieff, J., Munkholm, K., Hengartner, M. P., Kirsch, I., Gluud, C. N., & Jakobsen, J. C. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02221-5 · Cited by 5
Self-citationHow do we determine whether antidepressants are useful or not?
Horowitz, M. A., & Taylor, D. M. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30344-x · Cited by 5
Sanwald, S., Widenhorn‐Müller, K., Schönfeldt‐Lecuona, C., Montag, C., & Kiefer, M. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03215-0 · Cited by 5
O'Sullivan, M. (2022) · International Journal of Mental Health Nursing · doi:10.1111/inm.13054 · Cited by 4
Iosipchuk, O., Wylie, G. R., Motl, R. W., & Sandroff, B. M. (2025) · International Journal of MS Care · doi:10.7224/1537-2073.2024-003 · Cited by 5
Pharmacotherapy and psychotherapy in depression – complementarity or exclusion?
Mosiołek, A., & Podlecka, M. (2024) · Postępy Psychiatrii i Neurologii · doi:10.5114/ppn.2024.147104 · Cited by 7
“However, studies performed to date have many methodological limitations [58].”
Causal inference from clinical experience
Ghomi, H. T., & Stegenga, J. (2024) · Philosophical Studies · doi:10.1007/s11098-024-02264-x · Cited by 4
“Whether antidepressants have clinically relevant physiological effects is debated (Moncrieff & Kirsch, 2015; Munkholm et al., 2019).”
Davey, C. G., & Badcock, P. B. (2025) · Entropy · doi:10.3390/e27090970 · Cited by 3
“Although there is good evidence that antidepressants are effective for depression [17,18], it is true that treatment effect sizes are relatively small, with a substantial minority of patients not obtaining significant benefit [19].”
Sekechi, M., & Chiesa, M. (2022) · British Journal of Psychotherapy · doi:10.1111/bjp.12747 · Cited by 4
Fluoxetine Can Cause Epileptogenesis and Aberrant Neurogenesis in Male Wild-Type Mice
Musaelyan, K., Horowitz, M. A., McHugh, S. B., & Szele, F. G. (2023) · Developmental Neuroscience · doi:10.1159/000531478 · Cited by 3
Vittengl, J. R., Jarrett, R. B., Ro, E., & Clark, L. A. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230016 · Cited by 3
“Importantly, ADM effects are typically measured after weeks in RCTs [2,5], whereas community-dwelling adults often consume ADM for years [12,13].”
Carter, G. L., Sperandei, S., Chitty, K. M., & Page, A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12812 · Cited by 3
Suizidpräventive Effekte von Ketamin und Esketamin
Plöderl, M., Hengartner, M. P., & Volkmann, C. (2022) · Nervenheilkunde · doi:10.1055/a-1761-3192 · Cited by 2
Family Psychoeducation for Major Depressive Disorder: A Systematic Review
Obieche, O., Tan, J. (., Sharma, S., Bressington, D. T., Wang, T., & Li, M. (2025) · International Journal of Mental Health Nursing · doi:10.1111/inm.70205 · Cited by 2
Muñoz‐Navarro, R., Pérez‐Jover, V., Esteller-Collado, G., Román, C. J. V.-D. H., Salgueiro, M., Llorca, A., Malonda-Vidal, E., Canet-Cortell, V., Moraga-García, M. J., Coloma‐Carmona, A., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320857 · Cited by 2
“Despite the widespread use of antidepressants, long-term safety and effectiveness data are scant, mainly because most studies performed to date (many with important methodological limitations) have only evaluated the short-term effects (6–8 weeks) [57,60].”
Die homöopathische Behandlung von Depressionen
Koch, U. (2021) · Allgemeine Homöopathische Zeitung · doi:10.1055/a-1650-5046 · Cited by 2
Metadata
- Authors
- Munkholm, K., Paludan-Müller, A. S., & Boesen, K.
- Affiliations
- Rigshospitalet (DK)
- Corresponding author
- Munkholm, Klaus
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2019-06
- Volume
- 9
- Issue
- 6
- Pages
- e024886
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC6597641
- OpenAlex
- W2954134279
- Semantic Scholar
- 1f02503fe1b4290d23f35fdcf0ce927d794271ed
- Cited by
- 151
- References
- 43
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 17 · 2023: 31 · 2022: 20 · 2021: 29 · 2020: 15 · 2019: 11
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Nordic Cochrane Centre
- Topics
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- antidepressants, depression, placebo response, risk of bias, publication bias, clinical study reports, quality of evidence, Hamilton Depression Rating Scale, antidepressant efficacy
- MeSH terms
- Network Meta-Analysis, Network Meta-Analysis as Topic, Systematic Reviews as Topic, Adult, Antidepressive Agents, Depression, Humans, Meta-Analysis as Topic, Bias, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.